# US 2016/0354440 A1 · Methods for treating metabolic disorders using fgf

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354440 A1
- Document ID: US20160354440A1
- Status: Published application
- Kind: A1
- Application number: 15/240,803
- Filed: 2016-08-18
- Published: 2016-12-08
- Earliest claimed: 2010-04-16
- Assignees: The Salk Institute for Biological Studies
- Applicants: Salk Institute for Biological Studies
- Inventors: Johan W. Jonker; Michael Downes; Ronald M. Evans; Jae Myoung Suh
- Web page: https://patentgrep.com/patent/US20160354440A1

## CPC

- A61K 38/1825: {Fibroblast growth factor [FGF]}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/61: the organic macromolecular compound being a polysaccharide or a derivative thereof
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.

## Claims

### Claim 1

A method for reducing weight of a diabetic, hyperglycemic, and/or insulin resistant individual, comprising systemically administering an FGF-1 compound having at least 80% identity to human FGF-1 to the individual in an amount effective to reduce weight of the individual.

### Claim 2 (depends on 1)

The method of claim 1, wherein the FGF-1 compound is administered intravenously.

### Claim 3 (depends on 1)

The method of claim 1, wherein the FGF-1 compound is administered subcutaneously.

### Claim 4 (depends on 1)

The method of claim 1, wherein the FGF-1 compound is administered in combination with an additional therapeutic compound.

### Claim 5 (depends on 4)

The method of claim 4, wherein the additional therapeutic compound is an alpha-glucosidase inhibitor, amylin agonist, dipeptidyl-peptidase 4 (DPP-4) inhibitor, meglitinide, sulfonylurea, or a peroxisome proliferator-activated receptor (PPAR)-gamma agonist.

### Claim 6 (depends on 5)

The method of claim 5, wherein the PPAR-gamma agonist is a thiazolidinedione (TZD), aleglitazar, farglitazar, muraglitazar, or tesaglitazar.

### Claim 7 (depends on 6)

The method of claim 6, wherein the TZD is pioglitazone, rosiglitazone, rivoglitazone, or troglitazone.

### Claim 8 (depends on 1)

The method of claim 1, wherein the FGF-1 compound is a functional fragment of FGF-1 comprising at least 80% of human FGF-1.

### Claim 9 (depends on 8)

The method of claim 8, wherein the functional fragment of FGF-1 comprising at least 80% of human FGF-1 comprises at least 80% sequence identity to amino acids 1-140, amino acids 1-141, amino acids 14-135, or amino acids 13-135 of FGF1.

### Claim 10 (depends on 8)

The method of claim 8, wherein the functional fragment of FGF-1 comprising at least 80% of human FGF-1 comprises amino acids 1-140, amino acids 1-141, amino acids 14-135, or amino acids 13-135 of FGF-1.

### Claim 11 (depends on 8)

The method of claim 8, wherein the functional fragment of FGF-1 comprising at least 80% of human FGF-1 consists of amino acids 1-140, amino acids 1-141, amino acids 14-135, or amino acids 13-135 of FGF-1.

### Claim 12 (depends on 8)

The method of claim 8, wherein the functional fragment of FGF-1 comprising at least 80% of human FGF-1 comprises at least 80% sequence identity to amino acids 14-135 of FGF-1.

### Claim 13 (depends on 8)

The method of claim 8, wherein the functional fragment of FGF-1 comprising at least 80% of human FGF-1 comprises amino acids 14-135 of FGF-1.

### Claim 14 (depends on 8)

The method of claim 8, wherein the functional fragment of FGF-1 comprising at least 80% of human FGF-1 consists of amino acids 14-135 of FGF-1.

### Claim 15 (depends on 8)

The method of claim 8, wherein the functional fragment of FGF-1 comprising at least 80% of human FGF-1 comprises at least 90% sequence identity to amino acids 1-141 of FGF-1.

### Claim 16 (depends on 8)

The method of claim 8, wherein the functional fragment of FGF-1 comprising at least 80% of human FGF-1 comprises at least 95% sequence identity to amino acids 1-141 of FGF-1.

### Claim 17 (depends on 8)

The method of claim 8, wherein the functional fragment of FGF-1 comprising at least 80% of human FGF-1 comprises at least 98% sequence identity to amino acids 1-141 of FGF-1.

### Claim 18 (depends on 1)

The method of claim 1, wherein the FGF-1 compound is administered daily, twice daily, every other day, bi-weekly, weekly, or monthly.

### Claim 19 (depends on 1)

The method of claim 1, wherein the FGF-1 compound is at least 90% identical to mature human FGF-1.

### Claim 20 (depends on 1)

The method of claim 1, wherein the FGF-1 compound is a functional fragment of FGF-1 consisting of at least 90% of mature human FGF-1.

### Claim 21 (depends on 1)

The method of claim 1, wherein the individual has a body mass index (BMI) of 25 or higher

### Claim 22 (depends on 1)

The method of claim 1, wherein the individual has a BMI of greater than 30.

### Claim 23 (depends on 1)

The method of claim 1, wherein the individual has a BMI of 35 to 40.

### Claim 24 (depends on 1)

The method of claim 1, wherein the individual has a BMI of 40 or greater.

### Claim 25 (depends on 1)

The method of claim 1, wherein the method reduces food intake by the individual.

### Claim 26 (depends on 1)

The method of claim 1, wherein the individual is a human.
